Share

January 2023; 10 (1) Research ArticleOpen Access

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis

Chiara Starvaggi Cucuzza, Elisa Longinetti, Nicolas Ruffin, Björn Evertsson, Ingrid Kockum, Maja Jagodic, Faiez Al Nimer, Thomas Frisell, Fredrik Piehl
First published November 21, 2022, DOI: https://doi.org/10.1212/NXI.0000000000200056
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
885

Share

Article Information

vol. 10 no. 1 e200056
DOI: 
https://doi.org/10.1212/NXI.0000000000200056
PubMed: 
36411076
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received May 10, 2022
  • Accepted in final form September 16, 2022
  • First Published November 21, 2022.
Copyright & Usage: 
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Disclosures

    1. Chiara Starvaggi Cucuzza, MD,
    2. Elisa Longinetti, PhD,
    3. Nicolas Ruffin, PhD,
    4. Björn Evertsson, MD,
    5. Ingrid Kockum, PhD,
    6. Maja Jagodic, PhD,
    7. Faiez Al Nimer, MD, PhD,
    8. Thomas Frisell, PhD and
    9. Fredrik Piehl, MD, PhD
  1. Chiara Starvaggi Cucuzza, MD,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Elisa Longinetti, PhD,
    3. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. The Swedish Research Council for Health, Working Life, and Welfare (postdoc Grant No: 2020-0115 to E.L.)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Nicolas Ruffin, PhD,
    4. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Swedish StromaBio AB,

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Knut and Alice Wallenberg foundation, (2) NEURO Sweden, (3) MS forskningsfonden (4) Svenska Läkaresällskapets fonder SLS-961723,

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Björn Evertsson, MD,
    5. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Travel grant from Roche for ECTRIMS 2018.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Consultancies fees from Roche for writing a summery of ECTRIMS 2018.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Ingrid Kockum, PhD,
    6. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Stockholm county council (2018-2019) 800 000 SEK, 600 000 (2020-2021), SEK 1 750 000 (2022-2024)Karolinska Insitutet (2015-2020) PhD student funding 1 080 000 SEKEU Horizon 2020: MultipleMS consortium (2017-2021). Amount for whole consortium: 14,700 000 EURO, Share for my research group: 18 000 000 SEK EU Horizon 2020: EU STANDS-4PM consortium (2019-2021). Share for my research group: 61 875 EUROSwedish research council (2021-2024) SEK 4 800 000

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 100 year fonden at Karolinska Univiersity hospital during 2016 (150 000 SEK), "Hjärnfonden" during 2016, 2020-2023 as principal investigator (500 000, 600 00/year SEK respectively), Åke Löwnertz Stiftelse för Neurologisk Forskning 2018 (100 000 SEK). I have also received funding from Magareta af Ugglas Foundation (2015-2025) and PCORI (2017-2025) as co applicant.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. I and my mother have held stocks in a number of mainly Swedish companies. None of them are related to this study. Only one of them is involved medical research: Novo Nordisk which my mother has shares in.

    Legal Proceedings:

    1. NONE

    Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Stockholm county council (2018-2019) 800 000 SEK, 600 000 (2020-2021), SEK 1 750 000 (2022-2024)Karolinska Insitutet (2015-2020) PhD student funding 1 080 000 SEKEU Horizon 2020: MultipleMS consortium (2017-2021). Amount for whole consortium: 14,700 000 EURO, Share for my research group: 18 000 000 SEK EU Horizon 2020: EU STANDS-4PM consortium (2019-2021). Share for my research group: 61 875 EUROSwedish research council (2021-2024) SEK 4 800 000

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 100 year fonden at Karolinska Univiersity hospital during 2016 (150 000 SEK), "Hjärnfonden" during 2016, 2020-2023 as principal investigator (500 000, 600 00/year SEK respectively), Åke Löwnertz Stiftelse för Neurologisk Forskning 2018 (100 000 SEK). I have also received funding from Magareta af Ugglas Foundation (2015-2025) and PCORI (2017-2025) as co applicant.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. I and my mother have held stocks in a number of mainly Swedish companies. None of them are related to this study. Only one of them is involved medical research: Novo Nordisk which my mother has shares in.

    Legal Proceedings:

    1. NONE

  6. Maja Jagodic, PhD,
    7. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. (1) Physiological Genomics, Editorial Board member, 2015-2021(2) Frontiers in Neurology, Associate Editor, 2017-present(3) Scientific Reports, Editorial Board member, 2018-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) European Union’s Innovative Medicines Initiative 2, EUbOPEN (875510), co-investigator, 2020-2025(2) European Research Council (ERC) Consolidator Grant, Epi4MS (818170), lead investigator, 2019-2024(3) Swedish Research Council, (2018-02638), lead investigator, 2019-2022(4) Karolinska Institutet's funds, KID, lead investigator, 2019-2023(5) European Union’s Horizon 2020 Research and Innovation Programme, MultipleMS (733161), co-lead investigator, 2017-2022(6) Stockholm County Council, ALF project (20200278), lead investigator, 2021-2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) The Knut and Alice Wallenberg Foundation, (2019-0089), lead investigator, 2020-2024(2) The Brain Foundation (Hjärnfonden), (FO2021-0150), lead investigator, 2021-2024

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Faiez Al Nimer, MD, PhD,
    8. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Swedish Brain foundation (2) Neuro Sweden

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Thomas Frisell, PhD and
    9. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. The Swedish Research Council (DNR 2016-01355)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Fredrik Piehl, MD, PhD
    10. Scientific Advisory Boards:

    1. Data safety monitoring board member in studies with Roche and Lundbeck

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Janssen - academic research support relevant to this topic(2) Merck KGaA -academic research support relevant to this topic(1) UCB - academic research support outside of this topic

    Research Support, Government Entities:

    1. (1) Swedish Medical Research Council (grant 2020-02700) PI, 2020-ongoing.(2) Pcori, Washington DC (grant MS-1511-33196) PI, 2017-ongoing(3) European Union’s Horizon 2020 Research and Innovation Programme (MultipleMS, EU RIA 733161), co-investigator, 2017-ongoing

    Research Support, Academic Entities:

    1. (1) Stockholm County (grant 20200451), PI, 2020-ongoing.

    Research Support, Foundations and Societies:

    1. (1) the Knut and Alice Wallenberg Foundation(2) Hjärnfonden (grant FO2021-0277)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Novartis, expert witness statement, 2020-2021.

  1. From the Department of Clinical Neuroscience (C.S.C., E.L., N.R., B.E., I.K., M.J., F.A.N., F.P.), Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine (C.S.C., N.R., I.K., M.J., F.A.N., F.P.), Karolinska University Hospital, Stockholm, Sweden; Department of Neurology (B.E., F.P.), Karolinska University Hospital, Stockholm, Sweden; Center for Neurology (C.S.C., I.K., M.J., F.A.N., F.P.), Academic Specialist Center, Stockholm, Sweden; and Clinical Epidemiology Division (T.F.), Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  1. Correspondence
    Dr. Piehl fredrik.piehl{at}ki.se

Article usage

Article usage: November 2022 to October 2023

AbstractFullPdfSource
Nov 20223932180Highwire
Dec 20228649235Highwire
Jan 20231425479Highwire
Feb 2023417264Highwire
Mar 20231218776Highwire
Apr 20231211239Highwire
May 2023811635Highwire
Jun 2023210735Highwire
Jul 202369135Highwire
Aug 2023189237Highwire
Sep 2023129941Highwire
Oct 20231110129Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me